Boehringer Ingelheim once again turns to RNAi for new MASH therapies

Boehringer In­gel­heim is part­ner­ing with Chi­na-based biotech Suzhou Ri­bo Life Sci­ence and its Swe­den-based unit Ri­bo­cure Phar­ma­ceu­ti­cals to de­vel­op siR­NA ther­a­pies for meta­bol­ic dys­func­tion-as­so­ci­at­ed steato­hep­ati­tis (MASH), in a deal po­ten­tial­ly worth $2 bil­lion in biobucks.

The biotech will re­ceive an undis­closed up­front pay­ment, with fur­ther pay­outs if cer­tain clin­i­cal, reg­u­la­to­ry and com­mer­cial mile­stones are reached, as well as tiered roy­al­ties, per a press re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.